# EDGAR Filing Document

**Accession Number:** 0000315066
**File Stem:** 0000315066-23-002162
**Filing Date:** 2023-2
**Character Count:** 11402
**Document Hash:** c6cd253a39bf8cbefbaaf570f44d5721
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000315066-23-002162.hdr.sgml**: 20230209

**ACCESSION NUMBER**: 0000315066-23-002162

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230207

**FILED AS OF DATE**: 20230209

**DATE AS OF CHANGE**: 20230209

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** FMR LLC
- **CENTRAL INDEX KEY:** 0000315066
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41608
- **FILM NUMBER:** 23605656

**BUSINESS ADDRESS:**
- **STREET 1:** 245 SUMMER STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** 6175706339

**MAIL ADDRESS:**
- **STREET 1:** 245 SUMMER STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

**FORMER NAME:**
- **FORMER CONFORMED NAME:** FMR CORP
- **DATE OF NAME CHANGE:** 19920717
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Structure Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001888886
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 981480821
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 611 GATEWAY BLVD SUITE 223
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (628) 229-9277

**MAIL ADDRESS:**
- **STREET 1:** 611 GATEWAY BLVD SUITE 223
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ShouTi Inc.
- **DATE OF NAME CHANGE:** 20211019

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[x] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>FMR LLC<br><sub>(Last) (First) (Middle)</sub><br>245 SUMMER STREET<br><sub>(Street)</sub><br>BOSTON, MA 02210<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-02-07 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[ ] Officer (give title below) [X] Other (specify below)<br>_See Remark 1_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Structure Therapeutics Inc. [ GPCR ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Ordinary Shares | 2023-02-07 |  | C |  | 965115 | A | <sup>(1)</sup> | 965115 | I | F-Prime Capital Partners Life Sciences Fund VI LP |
| Ordinary Shares | 2023-02-07 |  | C |  | 57523 | A | <sup>(1)</sup> | 57523 | I | F-Prime Capital Partners Life Sciences Advisors Fund VI LP |
| Ordinary Shares | 2023-02-07 |  | C |  | 10154 | A | <sup>(1)</sup> | 67677 | I | F-Prime Capital Partners Life Sciences Advisors Fund VI LP |
| Ordinary Shares | 2023-02-07 |  | C |  | 7411 | A | <sup>(1)</sup> | 75088 | I | F-Prime Capital Partners Life Sciences Advisors Fund VI LP |
| Ordinary Shares | 2023-02-07 |  | C |  | 6947 | A | <sup>(1)</sup> | 82035 | I | F-Prime Capital Partners Life Sciences Advisors Fund VI LP |
| Ordinary Shares | 2023-02-07 |  | C |  | 3572022 | A | <sup>(1)</sup> | 3572022 | I | Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned |
| Ordinary Shares | 2023-02-07 |  | C |  | 568098 | A | <sup>(1)</sup> | 4140120 | I | Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned |
| Ordinary Shares | 2023-02-07 |  | C |  | 414621 | A | <sup>(1)</sup> | 4554741 | I | Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned |
| Ordinary Shares | 2023-02-07 |  | C |  | 214663 | A | <sup>(1)</sup> | 4769404 | I | Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Series A Convertible Preferred Shares | <sup>(1)</sup> | 2023-02-07 |  | C |  |  | 965115 | <sup>(1)</sup> | <sup>(1)</sup> | Ordinary Shares | 965115 | <sup>(1)</sup> | 0 | I | F-Prime Capital Partners Life Sciences Fund VI LP |
| Series A Convertible Preferred Shares | <sup>(1)</sup> | 2023-02-07 |  | C |  |  | 57523 | <sup>(1)</sup> | <sup>(1)</sup> | Ordinary Shares | 57523 | <sup>(1)</sup> | 0 | I | F-Prime Capital Partners Life Sciences Advisors Fund VI LP |
| Series A+ Convertible Preferred Shares | <sup>(1)</sup> | 2023-02-07 |  | C |  |  | 10154 | <sup>(1)</sup> | <sup>(1)</sup> | Ordinary Shares | 10154 | <sup>(1)</sup> | 0 | I | F-Prime Capital Partners Life Sciences Advisors Fund VI LP |
| Series B Convertible Preferred Shares | <sup>(1)</sup> | 2023-02-07 |  | C |  |  | 7411 | <sup>(1)</sup> | <sup>(1)</sup> | Ordinary Shares | 7411 | <sup>(1)</sup> | 0 | I | F-Prime Capital Partners Life Sciences Advisors Fund VI LP |
| Series B-1 Convertible Preferred Shares | <sup>(1)</sup> | 2023-02-07 |  | C |  |  | 6947 | <sup>(1)</sup> | <sup>(1)</sup> | Ordinary Shares | 6947 | <sup>(1)</sup> | 0 | I | F-Prime Capital Partners Life Sciences Advisors Fund VI LP |
| Series A Convertible Preferred Shares | <sup>(1)</sup> | 2023-02-07 |  | C |  |  | 3572022 | <sup>(1)</sup> | <sup>(1)</sup> | Ordinary Shares | 3572022 | <sup>(1)</sup> | 0 | I | Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned |
| Series A+ Convertible Preferred Shares | <sup>(1)</sup> | 2023-02-07 |  | C |  |  | 568098 | <sup>(1)</sup> | <sup>(1)</sup> | Ordinary Shares | 568098 | <sup>(1)</sup> | 0 | I | Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned |
| Series B Convertible Preferred Shares | <sup>(1)</sup> | 2023-02-07 |  | C |  |  | 414621 | <sup>(1)</sup> | <sup>(1)</sup> | Ordinary Shares | 414621 | <sup>(1)</sup> | 0 | I | Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned |
| Series B-1 Convertible Preferred Shares | <sup>(1)</sup> | 2023-02-07 |  | C |  |  | 214663 | <sup>(1)</sup> | <sup>(1)</sup> | Ordinary Shares | 214663 | <sup>(1)</sup> | 0 | I | Entities managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned |

---

### Footnotes:

(1) On February 7, 2023, in connection with the completion of the issuer's initial public offering, each share of  Series A, A+, B, and B-1 Preferred Shares converted on a 1-for-1 basis into Ordinary Shares.

**Remarks:**
Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110.
Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein.
Remark 3: F-Prime Capital Partners Life Sciences Advisors Fund VI LP (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VI LP. FPCPLSA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family.

**Signature:** Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson  
**Date:** 2023-02-09

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**